Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort
Josep M. Llibre(Badalona Serveis Assistencials), Adrián Curran(Lexington City Schools), Alexandra Montoliu(Vall d'Hebron Hospital Universitari), Nadia Abdulghani(Hospital Universitari de Santa Maria), Juan Tiraboschi(Bellvitge University Hospital), Juan Ambrosioni(Hospital Clínic de Barcelona), Lluís Force(University Hospital Mútua de Terrassa), Peré Domingo(Hospital de Sant Pau), Francisco Homar, Jordi Casabona(Generalitat de Catalunya), Joaquim Peraire(Instituto de Salud Carlos III), JM Miró(Hospital Clínic de Barcelona), Melchor Riera(Instituto de Salud Carlos III)
Cited by 38
Related Papers
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
|The Lancet Infectious Diseases|2015|143
Relationship between current level of immunodeficiency and non‐acquired immunodeficiency syndrome‐defining malignancies
|Cancer|2010|141
Highlights of the 2017 European <scp>AIDS</scp> Clinical Society (EACS) Guidelines for the treatment of adult <scp>HIV</scp>‐positive persons version 9.0
|HIV Medicine|2018|138
Less Lipoatrophy and Better Lipid Profile With Abacavir as Compared to Stavudine
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2006|137